Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction with breathing-related symptoms such as chronic cough, exertional dyspnea, expectoration, and wheeze. These symptoms may occur in conjunction with airway hyperresponsiveness and may be partially reversible. Although COPD is a nonspecific term referring to a set of conditions that develop progressively as a result of a number of different disease processes, it most commonly refers to chronic bronchitis and emphysema and a subset of patients with asthma. These conditions can be present with or without significant physical impairment. Despite being a very common disease and the fourth leading cause of death in the United States, COPD often is a silent and unrecognized disease, particularly in its early phases.

This article, the first of a 2-part series on COPD, reviews the epidemiology, clinical presentation, evaluation, and diagnosis of patients with COPD. The recently published Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for the classification of COPD are discussed. The importance of spirometry in identifying patients in the early stages of the disease is stressed. The second article in the series will use a case-based approach to review the management of COPD.

GOLD CRITERIA FOR COPD

Several different definitions have existed for COPD. The recently published and widely accepted definition from GOLD defines COPD as "a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases." Airflow limitation is the slowing of expiratory airflow as measured by spirometry, with a persistently low forced expiratory volume in 1 second (FEV₁) and a low FEV₁/FVC ratio despite treatment.

The GOLD definition for airflow limitation is an FEV₁/FVC ratio of less than 70%. Airways limitation reversibility can occur spontaneously, in response to a bronchodilator, or in response to oral or inhaled corticosteroids. The GOLD definition of COPD classifies reversibility as an FEV₁ increase of 200 mL and 12% improvement above baseline FEV₁ following administration of either inhaled corticosteroids or bronchodilators. Figure 1 depicts a spirometric tracing representative of a patient with COPD compared with a normal tracing.

The term partial reversibility describes patients who in fact have "reversibility" in response to administration of either corticosteroids or a bronchodilator, yet their best FEV₁ and FEV₁/FVC ratio classifies them as having airflow limitation.

Severity of COPD has typically been determined using the degree of lung function impairment, although the wisdom of this approach has been questioned recently, with the suggestion that other signs and symptoms, such as arterial blood gases values, body mass index, timed walking distance, and the sensation of dyspnea, be included in this determination.

The GOLD criteria classify COPD into 4 stages based primarily on lung function impairment (Table 1): Stage I (FEV₁ ≥ 80% predicted), Stage IIA (FEV₁ 50%–79% of predicted), Stage IIB (FEV₁ 30%–49% of predicted) and Stage III (FEV₁ < 30% of predicted). Additionally, GOLD lists a stage 0 level of disease, which describes persons who have normal lung function yet report respiratory symptoms such as chronic cough or sputum production.

Previous definitions of COPD differentiated between chronic bronchitis, asthma, and emphysema, acknowledging that there is frequently overlap between these disease entities. The GOLD definition of COPD does not differentiate between chronic bronchitis and emphysema but does note that although asthma and COPD can coexist, the largely reversible airflow limitation in asthma merits different therapeutic...
approaches than the largely irreversible airflow limitation of COPD.

EPIDEMIOLOGY
Prevalence of COPD

In national surveys in the United States, the primary means by which the prevalence of COPD has been determined has been by asking adults whether they have had any 1 of 17 respiratory diseases in the past 12 months. Three of the diseases asked about in this list are chronic bronchitis, emphysema, and asthma, with the estimate of COPD prevalence made by adding the cases of chronic bronchitis and emphysema. The National Health Interview Survey (NHIS) is an annually conducted, nationally representative survey of about 40,000 US households. In 1996, the estimated number of adults aged 18 years and older in the United States with COPD was 11.9 million.

The NHIS estimates for COPD have 2 important limitations. First, these estimates depend upon the proper recognition and diagnosis of COPD by both the study participants and their health care providers. This would tend to bias the estimates toward counting fewer cases than actually exist. A bias in the opposite direction, however, is that the term chronic bronchitis in this survey is not precisely defined and could be interpreted as recurrent episodes of acute bronchitis. The finding that “chronic bronchitis” has been reported in 3% to 4% of children supports the presence of this potential bias. The second limitation is that this survey is not able to validate, through physiologic evaluation, whether airway obstruction is present or absent.

These limitations were addressed, in part, by a separate nationally representative US survey. In the Third National Health and Nutrition Examination Survey (NHANES III), a stratified, multistage, clustered probability design was used to select a representative sample of the civilian, noninstitutionalized US population from 1988 through 1994. Survey participants completed extensive questionnaires in their homes, and received a comprehensive physical examination, including pulmonary function testing, at specially equipped mobile examination centers. Procedures for spirometric testing were based on the 1987 American Thoracic Society recommendations.

The NHANES III survey made it possible to determine the presence of airway obstruction, the prevalence of diagnosed COPD, and the estimated prevalence of COPD in the population of the United States. The application of the GOLD definition of COPD to the survey data resulted in an estimated national prevalence of 23.6 million adults or 13.9% of the adult population. An estimated 2.4 million adults, or 1.4% of the adult population, have moderate to severe airway obstruction, with an FEV₁ of less than 50% of the predicted value.

Thus, the majority of the subjects classified as having COPD by GOLD criteria (roughly 90%) have stage I or IIA disease. These data demonstrate that a large proportion of US adults with COPD are undiagnosed. Overall, 63% of the study population with evidence of COPD never had a diagnosis of lung disease, including 44% of subjects with an FEV₁ less than 50% of the predicted value.

A limitation of this survey—and most similar surveys—is that there was no determination of the reversibility of the airway obstruction, which is part of the GOLD definition of COPD. Many studies have looked at airway responsiveness (usually in response to methacholine or another nonspecific irritant), but that evaluation typically is done in a scenario of normal or near-normal lung function. The studies that do exist are often difficult to compare to each other because of differences in the way that reversibility is determined. For example, among participants in the Lung Health Study, 10.9% of patients with diagnosed mild COPD had at least a 10% improvement in their FEV₁ over their baseline FEV₁ in response to an inhaled bronchodilator. That study, however, excluded subjects with FEV₁ values of less than 50% of the predicted value.
their predicted value as well as subjects with variability in their FEV₁/FVC ratios. In a clinic-based study of subjects with COPD who were aged 69 years and older, 31% demonstrated reversibility, defined as a 15% improvement (from baseline) in FVC and FEV₁ following administration of an inhaled bronchodilator. In this latter study, subjects with more severe obstruction were more likely to have reversibility but would also be more likely to continue to have diminished lung function after maximum improvement was obtained, thus being classified as having “partial reversibility.”

The presence of significant reversibility or partial reversibility in patients with COPD and nonreversible airflow obstruction in asthma patients demonstrates that these diseases can coexist or, alternatively, that there is overlap and imprecision in the ways that these diseases are clinically diagnosed.

Morbidity and Mortality

COPD is a leading cause of disease morbidity and mortality in the United States. The National Center for Health Statistics (NCHS) conducts ongoing surveillance of several health indicators nationally. The NCHS collects physician office visit data using the National Ambulatory Medical Care Survey, hospitalization data using the National Hospital Discharge Survey and death data using the mortality component of the National Vital Statistics System. The following data include the number and rate of COPD events in adults in the United States (using International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM], codes 490, 491, 492 and 496) in these data sets for the most recent years available.

In 1998, COPD was responsible for an estimated 14.2 million ambulatory visits (to either hospital outpatient departments or physician offices), with a resulting rate of 82 visits per 1,000 population. COPD was also responsible for an estimated 1.4 million emergency room visits, with a resulting rate of 83 visits per 10,000 population.

COPD is a leading cause of hospitalization in US adults, particularly in older populations. In 1998, almost 662,000 hospitalizations, or 1.9% of total hospitalizations, were attributed to COPD. The rate of COPD hospitalizations (as the primary cause of hospitalization) was 38.3 per 10,000 population in 1998.

Deaths due to or associated with COPD have been steadily increasing in the United States over the past 20 years. While the death rate among men has plateaued, the rate among women has continued to

### Table 1. Classification of Chronic Obstructive Pulmonary Disease by Severity

<table>
<thead>
<tr>
<th>Stage</th>
<th>Characteristics*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0: at risk</td>
<td>Normal spirometry</td>
</tr>
<tr>
<td>I : mild COPD</td>
<td>Chronic symptoms (cough, sputum production)</td>
</tr>
<tr>
<td></td>
<td>FEV₁/FVC &lt; 70%</td>
</tr>
<tr>
<td></td>
<td>FEV₁ ≥ 80% of predicted</td>
</tr>
<tr>
<td></td>
<td>With or without chronic symptoms</td>
</tr>
<tr>
<td>IIA: moderate COPD</td>
<td>FEV₁/FVC &lt; 70%</td>
</tr>
<tr>
<td></td>
<td>50% of predicted ≤ FEV₁ &lt; 80% of predicted</td>
</tr>
<tr>
<td></td>
<td>With or without chronic symptoms</td>
</tr>
<tr>
<td>IIB: moderate COPD with the potential for severe exacerbations</td>
<td>FEV₁/FVC &lt; 70%</td>
</tr>
<tr>
<td></td>
<td>30% of predicted ≤ FEV₁ &lt; 50% of predicted</td>
</tr>
<tr>
<td></td>
<td>With or without chronic symptoms</td>
</tr>
<tr>
<td>III: severe COPD</td>
<td>FEV₁/FVC &lt; 70%</td>
</tr>
<tr>
<td></td>
<td>FEV₁ &lt; 30% of predicted or &lt; 50% of predicted plus the presence of respiratory failure† or clinical signs of right heart failure</td>
</tr>
</tbody>
</table>

COPD = chronic obstructive pulmonary disease; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity.

*All FEV₁ values refer to the postbronchodilator FEV₁.

†Respiratory failure defined as PaO₂ < 60 mm Hg with or without PaCO₂ > 50 mm Hg while breathing air at sea level.

increase. In 1998, 54,615 men and 51,377 women died of COPD. From 1995 to 1998, the rate of death attributable to COPD among men remained stable at 53.1 per 100,000 population (age-adjusted to the year 2000 US population), whereas the rate of death attributable to COPD among women increased 9.5%, from 29.3 to 32.1 per 100,000 (age-adjusted to the year 2000 US population). One of the limitations of using the mortality component of the National Vital Statistics System is that it is based on the underlying cause of death as reported on the death certificate; however, many decedents with COPD listed on the death certificate have their death attributed to another cause.

The significance of COPD as a contributor to death is undefined when it is present with diseases more likely to be attributed as the underlying cause of death, such as myocardial infarction or lung cancer.

COPD is a very costly disease, with estimated direct medical costs in 1993 of $14.7 billion. The estimated indirect costs related to morbidity (loss of work time and productivity) and premature mortality is an additional $9.2 billion, for a total of $23.9 billion. Because COPD may be present but not listed as the underlying cause of death or the primary reason for hospitalization, these cited estimates may underestimate the true cost of COPD.

Another manifestation of the importance of COPD is its effect on the burden of disease in a population determined using disability-adjusted life-years (DALYs). DALYs for a disease or condition are calculated as the sum of the years of life lost due to premature mortality in the population and the years of life lost due to disability. In 1996, COPD was estimated to be the eighth leading cause of DALYs among US men and the seventh leading cause of DALYs among US women. Worldwide, COPD is expected to move up from being the twelfth leading cause of DALYs in 1990 to the fifth leading cause in 2020.

**Gender Differences**

Smoking-related diseases such as COPD and lung cancer are continuing to increase among women in the United States, while they have plateaued or are decreasing among men. Some evidence has emerged that compared with men at a similar level of tobacco smoking, women may be more likely to develop COPD or that the severity of COPD in women may be increased. In the Lung Health Study, which evaluated patients with mild COPD, more women than men demonstrated increased airway responsiveness, although this difference was thought to be related to airway caliber rather than gender.

Adult women are more likely to both develop and die of asthma than are men. In NHANES III, whereas women reported more physician-diagnosed COPD and asthma than men, men and women had similar rates of decreased lung function, and a similar proportion of both men and women with...
low lung function had undiagnosed lung disease. The current evidence is inadequate to determine whether women who smoke are more likely to develop COPD or have more severe COPD than men, although this question is being studied by various groups.

RISK FACTORS AND ETIOLOGY

Smoking is the dominant risk factor for the development and progression of COPD; however, not all smokers develop COPD, and COPD does occur in persons who have never smoked, suggesting that other factors are important in the etiology of COPD. α1-Antitrypsin deficiency is an important cause of COPD in a very small percentage of cases. Other undefined genetic factors certainly play an important role in COPD development. The role of infections in both the development and progression of COPD is receiving increased attention, including the role of adenoviral infections in emphysema and the role of intracellular infections (eg, mycoplasma) in asthma. Occupational and environmental exposures to various pollutants (eg, particulate matter, agricultural dusts) are also important factors in the development of COPD.

CLINICAL PRESENTATION

COPD is heterogeneous in its presentation. Based on data from NHANES III, 44% of patients with severe airflow limitation (FEV1 < 50% of predicted) may not report symptoms. Among patients with severe airflow limitation who do report symptoms, the symptoms reported most frequently include wheezing (64%) and shortness of breath (65%). In recent years, COPD has been increasingly recognized as a systemic illness, with effects on nutritional status, muscle wasting, and depression. A large proportion of patients probably have components of chronic bronchitis, asthma, and emphysema occurring together. Although some of this overlap may be related to misdiagnosis, some of it may be a measure of the presence of airflow limitation reversibility. Better defining individuals in these groups may ultimately help tailor better interventions.

Key indicators for considering a diagnosis of COPD are listed in Table 2. These indicators are either the presence of symptoms (chronic cough, chronic sputum production, or dyspnea) or a history of smoking or exposure to occupational dusts or chemicals. Spirometry with an evaluation of bronchodilator response is then needed to establish a diagnosis of COPD. Based on data from NHANES III, at least 67% of the adult US population would have at least 1 of these indicators present. The proportion of the US...
population that has had pulmonary function testing is unknown but is thought to be very low. To address this problem, the National Lung Health Education Program (NLHEP) has been developed to educate both the public and physicians about the importance of COPD and to promote spirometry in primary care physician offices. NLHEP recommends that smokers older than 45 years and people with respiratory symptoms (eg, chronic cough, wheezing, dyspnea on exertion) have office-based spirometry performed. Abnormal findings on the office-based spirometry should be followed up with diagnostic-quality spirometry, including the determination of reversibility.

**DIAGNOSIS AND EVALUATION**

The evaluation of a patient with suspected COPD is oriented toward establishing the correct diagnosis and, once this has occurred, determining the extent of the impairment such that therapy can be appropriately targeted.

The differential diagnosis of COPD is listed in Table 3. While some of the other diagnoses listed are rare in the United States (eg, diffuse panbronchiolitis, obliterative bronchiolitis), others, such as asthma and congestive heart failure, are quite common. In addition, in underdeveloped regions of the world, bronchiectasis and tuberculosis continue to be very important and prevalent diseases.

Components in the evaluation of COPD are listed in Table 4. Every patient with suspected COPD should undergo a thorough history and physical examination. The history should pay particular attention to the following: exposure to risk factors; past history of asthma or allergic disease; family history of COPD; and, if a diagnosis of asthma has been made in the past, whether or not the symptoms are currently being controlled with bronchodilators.

---

**Table 4. Evaluation and Work-Up of Chronic Obstructive Pulmonary Disease**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Evaluation for all subjects with suspected COPD</strong></td>
<td>Should include the following:</td>
</tr>
<tr>
<td>History and physical examination</td>
<td>Exposure to risk factors</td>
</tr>
<tr>
<td></td>
<td>Past history of asthma or allergic disease</td>
</tr>
<tr>
<td></td>
<td>Family history of COPD</td>
</tr>
<tr>
<td></td>
<td>Presence of comorbid diseases</td>
</tr>
<tr>
<td></td>
<td>Effect of disease on patient's life, including ability to work and mental health status</td>
</tr>
<tr>
<td></td>
<td>Possibility for reducing risk factors, especially smoking cessation</td>
</tr>
<tr>
<td>Spirometry and bronchodilator response</td>
<td>FEV₁ and FVC should be measured, and the FEV₁/FVC ratio calculated, both before and after an inhaled bronchodilator. COPD severity (see Table 1) is assessed using the postbronchodilator lung function.</td>
</tr>
<tr>
<td><strong>Evaluation for subjects with confirmed moderate COPD</strong></td>
<td>Pulmonary function testing after a long-term (6-12 week) course of inhaled glucocorticosteroids, with reversibility present if FEV₁ increases at least 200 mL and 15% above baseline as compared to baseline.</td>
</tr>
<tr>
<td>Glucocorticosteroid reversibility testing</td>
<td>Seldom diagnostic in COPD, but useful to rule out other diagnoses</td>
</tr>
<tr>
<td></td>
<td>Computed tomography scans may be helpful in the presence of atypical findings on the chest radiograph</td>
</tr>
<tr>
<td>Chest radiograph</td>
<td>Should be performed in patients with FEV₁ &lt; 40% of predicted or with clinical signs suggestive of respiratory failure (cyanosis or ankle swelling) or right heart failure.</td>
</tr>
<tr>
<td>Arterial blood gas measurement</td>
<td>PaO₂ &lt; 60 mm Hg with or without PaCO₂ &gt; 50 mm Hg while breathing air at sea level suggests COPD-related respiratory failure.</td>
</tr>
<tr>
<td>α₁-Antitrypsin deficiency screening</td>
<td>Indicated in patients who develop COPD at a young age (&lt; 45 years) or who have a strong family history of COPD</td>
</tr>
</tbody>
</table>

COPD = chronic obstructive pulmonary disease; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity.

presence of comorbid diseases; effect of disease on the patient’s life, including ability to work and mental health status; and possibilities for reducing risk factors, especially smoking cessation. The physical examination is rarely diagnostic in COPD because most physical abnormalities do not occur until the advanced stages of the disease. Physical examination findings in patients with advanced disease include wheezing, prolonged expiration, decreased breath sounds, and an increased anterior-posterior diameter of the chest.

Pulmonary function testing, with assessment of response to a bronchodilator, is a critical part of the evaluation of suspected COPD. Whereas most patients with COPD can be managed by a primary care physician, patients with moderate or severe COPD should be evaluated by a specialist.

Once the diagnosis of moderate or severe COPD has been established, further testing, including glucocorticosteroid responsiveness, chest radiograph, arterial blood gas determination, and screening for α₁-antitrypsin deficiency may be indicated based on the patient’s history and/or clinical findings.

Treatment of COPD depends largely on the severity of the disease and will be covered in the second article in this series.

CONCLUSION

COPD is a common disease that is a leading cause of morbidity and mortality both in the United States and worldwide. Most—but not all—cases of COPD are attributable to smoking. Although its incidence among men has plateaued, it continues to increase among women. COPD, particularly in its early stages, is under-diagnosed in the United States. An increased awareness among physicians of the prevalence of mild COPD and the importance of spirometry in screening for and diagnosing the disease is important in combating the disease.

REFERENCES

1. Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development [review]. Chest 1998;113(4 Suppl):235S–41S.